Drugs / 20-19 Tan BB06oz CAR T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07701889 | Oct 2026 → Oct 2028 expected | hematologic disorder | Roswell Park Cancer Institute | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 20-19 Tan BB06oz CAR T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07701889 ↗ |
| Modality | Cell therapy | “genetically modified chimeric antigen receptor t-cell product” NCT07701889 ↗ |